Author: Curtis Carden — An international distributor of medicines, based in Charlotte, is upping its inventory of a drug in Europe that helps treat radiation and chemical exposure.
Tanner Pharma Group announced it is increasing the inventory of Leukine with the medication's owner, Partner Therapeutics, in response to Russia's invasion of Ukraine and the potential for incidents that could require a speedy deployment of the drug to treat people.
RELATED: Russia faces growing outrage amid new evidence of atrocities
"In response to the ongoing conflict in Ukraine, Tanner is supporting preparedness and response in Europe by increasing the local inventory of Leukine that can be rapidly deployed in response to an emergency," Banks Bourne, CEO and Founder of Tanner Pharma, said in a statement provided March 24. "The unique efficacy of Leukine, which has been shown to improve survival when given within 96 hours after radiation exposure and without whole blood transfusions, makes it a highly effective countermeasure with important logistical advantages in the event of a nuclear detonation. Positioning more supply in Europe ensures that more Leukine is available quickly, if needed."
Leukine was approved by the FDA in 2018 as a way to treat acute radiation syndrome and has been held for use in the United States since 2013.
According to the FDA report, "Leukine was shown to increase survival when administered up to 48 hours after total body irradiation exposure at doses expected to be fatal to 50% of those exposed subjects under conditions of minimal supportive care."
A press release provided by the company also mentioned that the drug was used to help treat some victims of the nuclear incident at the Chernobyl Nuclear Power Plant in 1986.
Tanner Pharma Group announced it is increasing the inventory of Leukine with the medication's owner, Partner Therapeutics, in response to Russia's invasion of Ukraine and the potential for incidents that could require a speedy deployment of the drug to treat people.
RELATED: Russia faces growing outrage amid new evidence of atrocities
"In response to the ongoing conflict in Ukraine, Tanner is supporting preparedness and response in Europe by increasing the local inventory of Leukine that can be rapidly deployed in response to an emergency," Banks Bourne, CEO and Founder of Tanner Pharma, said in a statement provided March 24. "The unique efficacy of Leukine, which has been shown to improve survival when given within 96 hours after radiation exposure and without whole blood transfusions, makes it a highly effective countermeasure with important logistical advantages in the event of a nuclear detonation. Positioning more supply in Europe ensures that more Leukine is available quickly, if needed."
Leukine was approved by the FDA in 2018 as a way to treat acute radiation syndrome and has been held for use in the United States since 2013.
According to the FDA report, "Leukine was shown to increase survival when administered up to 48 hours after total body irradiation exposure at doses expected to be fatal to 50% of those exposed subjects under conditions of minimal supportive care."
A press release provided by the company also mentioned that the drug was used to help treat some victims of the nuclear incident at the Chernobyl Nuclear Power Plant in 1986.
